TickerTalks
Browse all tickers →
TickerTalks›$PRAX
PRPRAX

Praxis Precision Medicines, Inc.

$PRAX·$7.2B·Biotechnology·Healthcare
$241.76-2.6%YTD-16.2%1Y+48.6%
Price updated 6h ago·X counts updated 5d ago
PRPRAX
$PRAXPraxis Precision Medicines, Inc.
$241.76-2.61%46 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PRAX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

46X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $PRAX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-13

Praxis Precision Medicines posts Q2 with $1.4B cash providing runway into 2028 as it preps two potential launches. Truist maintains Buy at $616 PT after the mid-cycle reviews for ulixacaltamide (ET, PDUFA Jan 29 '27) and relutrigine (SCN2A/8A DEEs, PDUFA Dec 27) showed no meaningful regulatory issues and no adcom meetings required.

Read what X is saying about $PRAX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PRAX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-10-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Biotech sitting on $1.4B cash with two PDUFAs inside the next 15 months — up 435% in a year because the de-risk is real.

Praxis Precision Medicines has done the thing CNS biotechs rarely do — bank a mid-cycle regulatory review on two drugs without a meaningful issue, lift the stock 435% in twelve months, and still have $1.4B of cash to execute both launches.

  • Relutrigine PDUFA December 27, 2026 (SCN2A/8A developmental epilepsies) and ulixacaltamide PDUFA January 29, 2027 (essential tremor) stack two orphan launches inside eight weeks — both drugs have real differentiation if labels are clean.
  • Sell-side modeling shows the P&L transition clearly — 2026 EPS -$13.60 to 2027 -$9.91 to 2028 +$5.80 to 2029 +$28.17 — with Truist at $616 PT and consensus coalescing around a buy rating as the mid-cycle review passed.
  • EPS surprises have been beats (Q2 $-2.87 vs $-3.67, Q1 $-3.20 vs $-3.58), narrower losses than the sell side modeled, which signals operational discipline into the launch builds.

At $295 and 72% of the 52-week range, the next three months are the setup — anything that reads as label breadth friendly at the December 27 PDUFA repositions the forward model, and the market has already been willing to pay for the de-risk.

Agrees with X sentimentX is bullish framing the Truist $616 PT and the mid-cycle review as the structural de-risk; the TickerTalks read agrees — the catalyst stack is explicit and the cash position supports commercial build regardless of launch pacing.

What to watch: December 27 relutrigine PDUFA and the label-breadth decision; January 29 ulixacaltamide PDUFA; November 9 Q3 earnings and any pre-launch commercial-infrastructure spending commentary.

On the calendar: Relutrigine PDUFA 2026-12-27

Read the AI verdict on $PRAX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops sodium and potassium channel modulators for epilepsy and neurological disorders in clinical trials.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PRAX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $PRAX

Neutral — Develops sodium and potassium channel modulators for epilepsy and neurological disorders in clinical trials.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-22.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-25.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-43.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-2.87$-3.67+21.8%
Q1 2026May 7, 2026$-3.20$-3.58+10.6%
Q4 2025Feb 19, 2026$-3.50$-3.13-12.0%
Q3 2025Nov 5, 2025$-3.36$-3.45+2.6%
Next earningsMon, Nov 9·consensus EPS $-3.54

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-3.20$-86.1M
Q4 FY25$0-100.0%——$-3.52$-77.3M
Q3 FY25$0-100.0%——$-3.36$-64.7M
Q2 FY25$0-100.0%——$-3.31$-54.8M

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$986K$709K – $1.3M-$13.60-$15.15 – -$12.3812
FY27$349.6M$169.6M – $482.1M-$9.91-$14.15 – -$3.7114
FY28$1.1B$511.5M – $2.1B$5.80-$7.98 – $32.2917
FY29$2.3B$1.0B – $4.2B$28.17$7.91 – $59.2913
FY30$3.6B$1.6B – $6.7B$52.57$14.76 – $110.648

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.37%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-24.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-23.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 24Jill DesimoneDirector11.6K sh$3.6M
+ 15 other (13 awards · 1 gift · 1 exempt) in window

See when $PRAX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Q2 2026 financial results on 2026-08-06, reporting financial results details in attached press release. Additional items: Item 7.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KMaterial eventJul 28-K — Item 4.01
AI summary

Praxis Precision Medicines dismissed Ernst and Young as independent auditor effective June 29, 2026; EY's clean opinions for FY2024 and FY2025 contained no adverse opinions, qualifications, or disagreements. No replacement auditor was named in the filing. Notable auditor change requiring investor attention; clean prior track record reduces immediate concern.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Praxis Precision Medicines held its 2026 Annual Meeting on June 10, 2026. Shareholders elected three Class III director nominees — Gregory Norden, Marcio Souza, and William Young — each to serve through 2029; ratified Ernst & Young LLP as independent auditor; and approved the advisory say-on-pay vote on executive compensation. Routine annual governance with no material business changes or contested outcomes.

8-KPress release / Reg FDMay 78-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PRAX reported period ending 2026-05-13 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

+ 14 other (6 13Gs · 4 routine 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·14d agoReviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)defenseworld.net·15d agoPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of “Moderate Buy” by Brokeragesdefenseworld.net·26d agoPraxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)seekingalpha.com·35d agoPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·43d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $PRAX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport